1-4 of 4
Ulla Strömberg
Close
Sort by
Journal Articles

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

Francois-xavier Mahon, MD PhD, Johan Richter, MD, Joelle Guilhot, PhD, Henrik Hjorth-Hansen, MD PhD, Antonio Almeida, MD PhD, Jeroen J.W.M. JWM Janssen, MD, Jiri Mayer, Kimmo Porkka, MD PhD, Panayiotis Panayiotidis, MD PhD, Ulla Stromberg, MDPhD, Marc G Berger, MD PhD Professor, Joanna Diamond, Hans Ehrencrona, MD PhD, Veli Kairisto, Katerina Machova Polakova, Martin C. Mueller, Prof., Satu Mustjoki, MD PhD, Andreas Hochhaus, MD, Markus Pfirrmann, PhD, Susanne Saussele, MD
Journal: Blood
Blood (2016) 128 (22): 787.
https://doi.org/10.1182/blood.V128.22.787.787
Published: 2016
Journal Articles

Phenotypic and Functional Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Chronic Myeloid Leukemia

Monika Dolinska, Johannis Klang, Pingnan Xiao, MD, Andranik Durgaryan, Lakshmi Sandhow, Anne-Sofie Johansson, Makoto Kondo, Stefan Deneberg, MD, PhD, Johanna Ungerstedt, Associate Professor, Katarina Le Blanc, MD, PhD, Leif Stenke, MD PhD, Marja Ekblom, Ulla Stromberg, MDPhD, Satu Mustjoki, MD PhD, Soren Lehmann, MD PhD, Hong Qian, PhD
Journal: Blood
Blood (2015) 126 (23): 2398.
https://doi.org/10.1182/blood.V126.23.2398.2398
Published: 2015
Journal Articles

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Henrik Hjorth-Hansen, MD PhD, Jesper Stentoft, Johan Richter, MD PhD, Perttu Koskenvesa, MD, Arta Dreimane, MD, Kimmo Porkka, MD PhD, Tobias Gedde-Dahl, MDPhD, Bjorn Gjertsen, MD PhD, Franz X. Gruber, MDPhD, Martin Hoglund, MD PhD, Anna Lubking, MD, Kristina Myhr-Eriksson, MD, Berit Markevärn, Hanne Vestergaard, MDPhD, Ole Weis Bjerrum, MDPhD, Leif Stenke, MDPhD, Satu Mustjoki, MD PhD, Ulla Stromberg, MDPhD
Journal: Blood
Blood (2015) 126 (23): 477.
https://doi.org/10.1182/blood.V126.23.477.477
Published: 2015
Journal Articles

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Clinical Trials & Observations
Bengt Simonsson, Tobias Gedde-Dahl, Berit Markevärn, Kari Remes, Jesper Stentoft, Anders Almqvist, Mats Björeman, Max Flogegård, Perttu Koskenvesa, Anders Lindblom, Claes Malm, Satu Mustjoki, Kristina Myhr-Eriksson, Lotta Ohm, Anu Räsänen, Marjatta Sinisalo, Anders Själander, Ulla Strömberg, Ole Weiss Bjerrum, Hans Ehrencrona, Franz Gruber, Veli Kairisto, Karin Olsson, Fredrik Sandin, Arnon Nagler, Johan Lanng Nielsen, Henrik Hjorth-Hansen, Kimmo Porkka, for the Nordic CML Study Group
Journal: Blood
Blood (2011) 118 (12): 3228–3235.
https://doi.org/10.1182/blood-2011-02-336685
Published: 2011